HIGH QUALITY SERVICE

high technology innovation , high speed development.

HIGH QUALITY SERVICE

肝癌 TMA

上海芯超生物科技有限公司 
生物芯片上海国家工程研究中心

上海市高新技術企業

  • 上海芯超生物科技有限公司成立於2003年12月18日
  • 為美國BIOXXX 組織晶片公司之上游供應商

擁有十五863消化道腫瘤組織庫與組織芯片重大項目、十一五863胰腺癌基因組重大項目、衛生部肝癌組織芯片分子標記物篩選重大項目、863胃癌易感基因與幽門螺桿菌耐藥基因聯合檢測重點項目。

商品介紹

Catalog

Diameter

Dots

Cases

Description

HLiv-Dis051Bch-01

2.0mm

51

20

1. Liver disease (20 cases), containing hepatocellular carcinoma (9 cases), cholangiocellular carcinoma (2 cases), hepatic adenoma (1 case), cirrhosis (3 cases) and hepatic hemangioma (5 cases). 
2. Biochemical indicator available (AFP,HBV,HCV RNA).

HLiv-Dis060PT-01

1.5mm

60

47

1. Liver hyperplasia tissue, hepatocirrhosis tissue, hepatocellular carcinoma with normal adjacent tissue,  hepatoblastoma, intrahepatic cholangiocarcinomas, mixed carcinoma of liver, fibroblastoma, angeioma, sarcomatoid carcinoma, lipoma.

HLivH030PG02

2.0mm

30

30

Hepatocellular carcinoma (30 cases),tumor 1 core/case. Pathology grade:I-Ⅲ

HLivH060CD03

2.0mm

60

40

Progress of  liver carcinoma: normal liver tissue, liver cirrhosis tissue, remote/normal adjacent tissue/primary tumor tissue (clinical stage Ⅰ to Ⅳ), metastasis of liver cancer.
1 core/case, 2~17 cases for each progress.

HLivH060CS01

2.0mm

60

31

2 cases of normal liver tissue.Hepatocellular carcinoma (29 cases),tumor and normal adjacent tissue, 1 core/case.with TNM score.clinical stage(AJCC 7.0) I-Ⅲ.

HLivH090BC01

2.0mm

90

70

hepatocellular carcinoma 70 cases, with IHC results, clinical stage Ⅱ- Ⅳ

HLivH090PG01

1.5mm

90

30

Hepatocellular carcinoma (30 cases),tumor,normal adjacent tissue and remote normal tissue, 1 core/case. Pathology grade:I-Ⅲ

HLivH150CS03

1.5mm

150

75

1. Hepatocellular carcinoma (75 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
2. Clinical stage I (20cases), II (25 cases), III (22 cases), IV (8 cases).  
3.100% cases have TNM detail information.   
4. Pathology grade 1, 2, 3.   (67 cases overlapped with LivH150CS02)

HLiv-HCC030PG-01

2.0mm

30

15

1. Hepatocellular carcinoma (15 cases), tumor (1 cores/case) and matched normal adjacent tissue (1 cores/case).  
2. Pathology grade 1, 2, 3.

HLiv-HCC050PG-01

2.0mm

50

25

1. Hepatocellular carcinoma (23 cases) and intrahepatic cholangiocellular carcinoma (2 cases). Tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 1, 2, 3.
3. Paired frozen tissue accessible.

Hliv-HCC058PG-01

2.0mm

58

29

1. Hepatocellular carcinoma (25 cases), intrahepatic cholangiocellular carcinoma (1 case), hepatic adenoma (2 cases) and poorly differentiated carcinoma (1 case). 2 cores/case. 
2. Pathology grade 1, 2, 3.
3. Paired frozen samples accessible.

Hliv-HCC060PG-01

2.0mm

60

30

1. Hepatocellular carcinoma (30 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 1(1 case),  1-2(1 case),  2 (16 cases), 2-3(6 cases),  3 (6 cases).

HLiv-HCC180Bch-01

1.5mm

180

49

1. Hepatocellular carcinoma (49 cases), 41 cases have tumor (2 cores/case) and matched normal adjacent tissue (2 cores/case). 6 cases have tumor tissue (2 cores/case). 2 cases have normal adjacent tissue (2 core/case).  Pathology grade 1, 2, 3. 
3. Biochemical indicator available (AFP,HBV,HCV RNA, Creatinine, Urea nitrogen, CEA).

Hliv-HCC180Sur-03

1.5mm

180

90

1. Hepatocellular carcinoma (90 cases). Tumor (1 core/case) and NAT (1 core/case).
2. Survival Information available.
3. Surgery date 2010.1-2011.9. Visit date 2013.9. Being followed up for 2-3.7 years.

HLiv-HCC180Sur-04

1.5mm

180

90

1. Hepatocellular carcinoma (90 cases). Tumor (1 core/case) and NAT (1 core/case).
2. Survival Information available.
3. Surgery date 2006.8-2009.11. Visit date 2013.9. Being followed up for 4-7 years.
4. 85 cases overlapped with HLiv-HCC180Sur-02

HLiv-HCC180Sur-05

1.5mm

180

90

1. Hepatocellular carcinoma (90 cases). Tumor (1 core/case) and NAT (1 core/case).
2. Survival Information available.
3. Surgery date 2006.8-2009.11. Visit date 2013.9. Being followed up for 4-7 years.
4. 85 cases overlapped with HLiv-HCC180Sur-02

HLiv-Mix036PG-01

2.0mm

36

18

1. Mixed carcinoma of liver, 18 cases. Tumor and matched normal adjacent tissue. 2 cores/case.

OD-CT-DgLiv01-002

1.0mm

200

110

1. Liver carcinoma (80 cases), 2 cores/case.  Normal adjacent tissue (10 cases), 2 cores/case. Other tumor tissue (20 cases), 1 core/case.
2. Pathology grade 1, 2, 3.

OD-CT-DgLiv01-003

1.0mm

224

56

1. Liver carcinoma (56 cases), containing hepatocellular carcinoma ( 38 cases, pathology grade I, II, III) and other liver carcinoma(18 cases, cholangiocellular carcinoma, liver adenocarcinoma, liver squamous cell carcinoma, Hepatic hemangioma, Cyst and hyperplasia).

OD-CT-DgLiv01-004

1.0mm

224

56

1. Hepatocellular carcinoma (56 cases), tumor (2 cores/case) and matched normal adjacent tissue (2 cores/case).  
2. Pathology grade 2, 3.

OD-CT-DgLiv01-008

1.0mm

375

125

1. Hepatocellular carcinoma (100 cases, pathology grade  I, II, III).  
2. Sclerosing hepatocellular carcinoma (5 cases)  
3. Liver cirrhosis (20 cases) 
4.  3 cores/case.

OD-CT-DgLiv01-012

1.5mm

106

55

1. Hepatocellular carcinoma (55 cases) with survival information. 51 cases have tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  4 cases have tumor (1 core/case) or normal adjacent tissue (1 core/case).  
2. Clinical stage I-IV (Version 7.0).
3. Surgery date 2006.8-2008.12 , visit date 2013.9. Being followed up for 4.8-7 years.

OD-CT-DgLiv02-001

2.0mm

32

32

1. Hepatocellular carcinoma (32 cases), 1 core/case.  
2. Pathology grade 1, 1-2.

OD-CT-DgLiv02-002

2.0mm

32

32

1. Hepatocellular carcinoma (32 cases), 1 core/case.  
2. Pathology grade 2.

OD-CT-DgLiv02-003

2.0mm

32

32

1. Hepatocellular carcinoma (32 cases), 1 core/case. 
2. Pathology grade 2-3, 3.

OD-CT-DgLiv02-004

2.0mm

38

38

1. Hepatocellular carcinoma (38 cases), 1 core/case. 
2. Pathology grade 1, 2, 3.

OD-CT-DgLiv02-005

2.0mm

26

13

1. Hepatocellular carcinoma (13 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
2. Pathology grade 1, 2, 3.

OD-CT-DgLiv03-001

2.0mm

62

62

1. Hepatocellular carcinoma (62 cases), 1 core/case. 
2. Pathology grade 1, 2, 3.

OD-CT-DgLiv03-002

2.0mm

62

31

1. Hepatocellular carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   
2. Pathology grade 2, 2-3.

OD-CT-DgLiv03-003

2.0mm

62

31

1. Hepatocellular carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 1 (5 cases),  1-2 (5 cases),  2 (16 cases),  2-3 (5 cases).

OD-CT-DgLiv03-004

2.0mm

62

31

1. Hepatocellular carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 2.

OD-CT-DgLiv04-001

2.0mm

82

41

1. Hepatocellular carcinoma (41 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 1, 2, 3. 
3. Paired frozen samples accessible.

OD-CT-DgLiv04-002

1.5mm

85

40

1. Hepatocellular carcinoma (40 cases), 2 cores/case. Normal adjacent tissue (5 cases), 1 core/case. 
2. Pathology grade 1 , 2, 3.
3. TNM score available.

HLivH180Su06

1.5mm

180

90

Hepatocellular carcinoma, 90 cases. Tumor and NAT*.Surgery date 2006.2－2007.5，Visit date 2012.2。 Being followed up for 5－6 years. Clinical stage I & II.With recurrence date and biochemistry indicates.

HLivH180Su10

1.5mm

180

95

1. Liver carcinoma, 93 cases, 93 cases of tumor and 87 cases of NAT*.
2. Survival information available. Surgery date 2007.1－2009.11，visit date 2013.9. Being followed up for 4－6.7 years.